Avid Bioservices Inc

Avid Bioservices — Investor Presentation (December 2023)

18 slides from Avid Bioservices's investor presentation, Dec 6, 2023

  1. Slide 1: Corporate Presentation December 2023

    Corporate Presentation December 2023

  2. Slide 2: Safe Harbor Statement

    2 CONFIDENTIAL Safe Harbor Statement Some of the statements in this presentation contain forward - looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchang

  3. Slide 3: Corporate Highlights: Rapidly Growing, Full-Service, Customer-Centric Biologics CDMO

    3 CONFIDENTIAL Experienced management and board with expertise in high - growth, large - scale therapeutic manufacturing with deep understanding of regulatory environment Demonstrated history of investment with recent facility expansions adding world - leading capabilities in mammalian and cell and

  4. Slide 4: Accomplished Leadership Team with Experience to Deliver on Growth Strategy

    4 CONFIDENTIAL Accomplished Leadership Team with Experience to Deliver on Growth Strategy Chief Financial Officer Daniel Hart (experience: 25+ yrs) Chief Commercial Officer Matthew Kwietniak (experience: 30+ yrs) Chief Operations Officer Richard Richieri (experience: 25+ yrs) VP, Quality Ray Marzouk

  5. Slide 5: Year Proven Track Record of Operational Excellence, Success and Investment in the Future

    5 CONFIDENTIAL 30 - Year Proven Track Record of Operational Excellence, Success and Investment in the Future Approved manufacturer of products marketed in 90 + c o u n t r i e s 21 Years of successful inspection history 18 Years of CGMP commercial manufacturing 8 Successful pre - approval / pre - li

  6. Slide 6: Long History of Successful Regulatory Inspections + Global Reputation for Quality

    6 CONFIDENTIAL Long History of Successful Regulatory Inspections + Global Reputation for Quality • Over 200 commercial batches produced • 21 years of successful inspection history • Manufacture commercially approved drug substances that go into drug products that are marketed in over 90 countries •

  7. Slide 7: Well Positioned to Serve Fastest Growing Biologics Drug Substance Market Segment

    7 CONFIDENTIAL Well Positioned to Serve Fastest Growing Biologics Drug Substance Market Segment Non - Disposable Mammalian Drug Substance Market Disposable Mammalian Drug Substance Market 2022 Actual 2027 Projected Disposable biologics market expected to double by 2027; fastest growing segment of th

  8. Slide 8: Powerful Tailwinds Driving Market to Avid

    8 CONFIDENTIAL Powerful Tailwinds Driving Market to Avid Growing Biologics Demand Decreasing Reactor Size Requirements Increased Outsourcing Avid Well Positioned with New State - of - the - Art Mammalian and C&GT Capacity Built on a Disposable Platform • Disposables forecast to be the fastest growin

  9. Slide 9: Broad Spectrum of Service Offerings and Capabilities

    9 CONFIDENTIAL Broad Spectrum of Service Offerings and Capabilities One of the few CDMOs offering a comprehensive range of services from cell line and process development through commercial - stage CGMP manufacturing Customer - Focused Approach Agile & Collaborative Industry - Leading Track Record A

  10. Slide 10: $400M+ of Revenue-Generating Capacity Sets Stage for Continued Growth

    10 CONFIDENTIAL $400M+ of Revenue - Generating Capacity Sets Stage for Continued Growth Avid deployed more than $180 million of capital from 2020 – 2023 into expansions of both revenue - generating capacity and technical capabilities Note: Dollar amounts represent total estimated revenue - generatin

  11. Slide 11: Key Growth Drivers: Dynamic Growth Engine Driven by Customer Acquisition and Expansion

    11 CONFIDENTIAL Key Growth Drivers Dynamic Growth Engine Driven by Customer Acquisition and Expansion Activities: Designed to Accelerate Growth in Attractive and Expanding Market Growing reputation and outreach continues to add to growing customer base Customers’ clinical success drives future and t

  12. Slide 12: Established Track Record of Growth: 150% Increase Over Past Three Years

    12 CONFIDENTIAL 58% $34.4M 28% $16.7M 14% $8.6M Established Track Record of Growth: 150% Increase Over Past Three Years FY 2020 $60M in Revenue FY 2023 $149M in Revenue 26% $38.5M 45% $67.8M Commercial Late - Stage Clinical Other Clinical 29% $42.9M Late - stage + commercial 42% $25M Clinical 72% $4

  13. Slide 13: Diversified, Growing and Maturing Portfolio Across Mammalian Modalities

    13 CONFIDENTIAL Diversified, Growing and Maturing Portfolio Across Mammalian Modalities 49% 13% 12% 11% 9% 6% Monoclonal Antibody ADC intermediate Fusion Protein/ Bispecific Antibody Enzyme Recombinant Protein Vaccine 2018 2019 2020 Calendar Year 2021 2022 Phase 3/Pre - Commercial Phase 2 Pre - Clin

  14. Slide 14: Increase in Later-Stage Pipeline with Significant Recurring Commercial Revenue Potential

    14 CONFIDENTIAL Increase in Later - Stage Pipeline with Significant Recurring Commercial Revenue Potential P1 PII PIII P1 PII PIII P1 PII PIII P1 PII PIII P1 PII PIII 2018 2019 2020 2021 2022 Calendar Year Number of Projects P1 PII PIII P1 PII PIII P1 PII PIII P1 PII PIII P1 PII PIII 2018 2019 2020

  15. Slide 15: High Level of Revenue Visibility as Backlog Outstrips Revenue Growth

    15 CONFIDENTIAL High Level of Revenue Visibility as Backlog Outstrips Revenue Growth with Increasing Number of Later - Phase Programs Revenue Growth Backlog Growth $52M $84M $99M $125M $8M $12M $20M $24M FY 2020 FY 2021 FY2022 FY2023 Manufacturing Process Development $65M $118M $153M $191M FY 2020 F

  16. Slide 16: Strong Financial Position: Positive Forward-Looking Trajectory with Low Capital Requirements

    16 CONFIDENTIAL Strong Financial Position: Positive Forward - Looking Trajectory with Low Capital Requirements Recent facility expansion completions fundamentally change the company’s go - forward business and financial position Business: • Increased revenue - generating capacity to $400M+ • Provide

  17. Slide 17: Corporate Highlights: Rapidly Growing, Full-Service, Customer-Centric Biologics CDMO

    17 CONFIDENTIAL Experienced management and board with expertise in high - growth, large - scale therapeutic manufacturing with deep understanding of regulatory environment Demonstrated history of investment with recent facility expansions adding world - leading capabilities in mammalian and cell and

  18. Slide 18: Thank You

    AVID- ~ BIOSERVICES Where collaboration, quality, and reliability meet Thank You December 2023

Avid Bioservices — Investor Presentation (December 2023) on 6ix